TAR-210-Ergebnisse zeigen rezidivfreies Überleben von 90 Prozent und vollständiges Ansprechen von 90 Prozent bei Patienten mit nicht-muskelinvasivem Blasenkrebs mit hohem bzw. mittlerem Risiko
May 09, 2024 05:44 ET
|
Janssen Cilag International NV
Aktualisierte Ergebnisse bekräftigen das Potenzial von TAR-210, die Behandlung von nicht-muskelinvasivem Blasenkrebs mit Veränderungen des Fibroblasten-Wachstumsfaktor-Rezeptors (FGFR) zu...
Global Outdoor Furniture Business Analysis Report 2024-2030: Innovations Blur the Difference between Outdoor and Indoor Furniture, Innovative Weather Resistant Materials & Fabrics Fuel Demand
May 09, 2024 05:35 ET
|
Research and Markets
Dublin, May 09, 2024 (GLOBE NEWSWIRE) -- The "Outdoor Furniture - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Outdoor Furniture Market to...
Global Antimicrobial Coatings Industry Research 2024-2030: A Powerful Solution for Biomedical Applications, Spiraling Popularity for Medical Devices, Revival in Construction Spurs Growth
May 09, 2024 05:23 ET
|
Research and Markets
Dublin, May 09, 2024 (GLOBE NEWSWIRE) -- The "Antimicrobial Coatings - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Antimicrobial Coatings...
Himax Technologies, Inc. Reports First Quarter 2024 Financial Results; Provides Second Quarter 2024 Guidance
May 09, 2024 05:20 ET
|
Himax Technologies, Inc.
Q1 2024 Revenues, EPS and Gross Margin All Exceeded Guidance Range Issued on February 6, 2024Company Q2 2024 Guidance: Revenues to Increase 8% to 13% QoQ,Gross Margin is Expected to be 31.5% to 33.5%,...
Los datos del ensayo de fase 2 sobre ERLEADA®▼(apalutamide) más terapia de privación androgénica tras prostatectomía radical en pacientes con cáncer de próstata localizado de alto riesgo muestran una tasa de recidiva libre de efectos bioquímicos del 100 por ciento más de dos años después de la cirugía
May 09, 2024 05:12 ET
|
Janssen Cilag International NV
El estudio destaca la oportunidad de intensificar el tratamiento en esta población, ya que aproximadamente el 50 por ciento de los pacientes con cáncer de próstata localizado de alto riesgo (CPAR)...
Phase-II-Daten für ERLEADA®▼(apalutamide) plus Androgendeprivationstherapie nach radikaler Prostatektomie bei Patienten mit lokal begrenztem Hochrisiko-Prostatakrebs zeigen 100 prozentige biochemische Rezidivfreiheit mehr als zwei Jahre nach der Operation
May 09, 2024 05:12 ET
|
Janssen Cilag International NV
Die Studie unterstreicht die Möglichkeit einer Intensivierung der Behandlung in dieser Patientengruppe, da bei etwa 50 Prozent der Patienten mit lokalisiertem Hochrisiko-Prostatakrebs (High-risk...
Dati della Fase 2 di ERLEADA®▼(apalutamide) più trattamento di deprivazione androgenica in seguito a prostatectomia radicale in pazienti affetti da tumore della prostata localizzato ad alto rischio mostrano un tasso del 100 percento di assenza di recidiva biochimica più di due anni dopo l'intervento
May 09, 2024 05:12 ET
|
Janssen Cilag International NV
Lo studio evidenzia l'opportunità di intensificare il trattamento in tale popolazione poiché approssimativamente il 50 percento di pazienti con tumore della prostata localizzato ad alto rischio...
Données de phase 2 pour ERLEADA®▼(apalutamide) en association avec un traitement par privation androgénique après une prostatectomie radicale chez des patients atteints d’un cancer de la prostate localisé à haut risque : un taux de survie sans récidive biochimique de 100 pour cent plus de deux ans après l’intervention chirurgicale
May 09, 2024 05:11 ET
|
Janssen Cilag International NV
L’étude met en évidence la possibilité d’intensifier le traitement pour cette population, puisque près de 50 pour cent des patients atteints d’un cancer de la prostate localisé à haut risque (CPLHR)...
Nano Positioning System Market To Reach USD 254.8 Billion By 2032 | DataHorizzon Research
May 09, 2024 05:10 ET
|
DataHorizzon Research
Fort Collins, Colorado, May 09, 2024 (GLOBE NEWSWIRE) -- High demand for precision in the manufacturing industry drives industry developments. The nano positioning system market is experiencing...
Global Defense Electronics Obsolescence Industry Research 2023-2028: Opportunities in Remanufacturing and Reverse Engineering Adoption and Modular Designs to Future-Proof Defense Electronics
May 09, 2024 04:39 ET
|
Research and Markets
Dublin, May 09, 2024 (GLOBE NEWSWIRE) -- The "Global Defense Electronics Obsolescence Market by System (Communication System; Navigation System; Human Machine Interface; Flight Control System;...